Green Paula sold 20,429 shares of TWST
Green Paula (SVP of Human Resources) sold 20,429 shares of Twist Bioscience Corp (TWST) on 2026-11-12.
Twist Bioscience Corp
Twist Bioscience develops and manufactures synthetic DNA and related products using a platform that writes DNA on silicon chips. Its customers include life sciences researchers, biotechnology and pharmaceutical companies, diagnostic companies, hospitals, research institutions, agricultural biotechnology companies, industrial chemical companies and academic labs. Twist’s products include synthetic biology tools such as genes, gene fragments, oligonucleotide pools, RNA and proteins; next-generation sequencing tools, including library preparation kits and target enrichment panels; and synthetic controls. It also provides biopharma services for antibody discovery, optimization and development, including screening, assays, antibody expression and characterization. Twist makes money by selling products and services, and earns licensing and service fees from antibody partnerships, which may also include success-based milestones and royalties. It sells worldwide through direct sales, consultants, e-commerce and distributors. Twist is headquartered in South San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Green Paula (SVP of Human Resources) sold 20,429 shares of Twist Bioscience Corp (TWST) on 2026-11-12.
Barclays maintained Twist Bioscience's Overweight rating but lowered its price target to $130 from $215, a 39.5% decrease. The new target implies a 16.5% upside from the Nov 13 close of $111.60. Recent analyst price targets for Twist range from $135 to $175.
ARK Invest added $16.2M to NVIDIA (NVDA) and $16M to CoreWeave (CRWV), while reducing positions in Tempus AI (TEM) and Palantir (PLTR) by $12.8M and $11.8M, respectively. Other buys included ACHR, TWST, PRME, and SOFI. Sells included AMZN, TER, SNPS, AVGO, XYZ, and BYDDY.
Over the past 7 days, AlphAI's AI scored 31 news stories mentioning TWST (Twist Bioscience Corp). Coverage has been balanced: 14 bullish, 3 neutral, and 14 bearish.
Recent TWST coverage spans financial news, earnings and insider activity.
In the last 30 days, TWST insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($1.6M). The most active reporter was Green Paula, SVP of Human Resources, with 2 filings.
Insider selling can modestly pressure sentiment, but the filing provides no price or value and no 10b5-1 plan, limiting signal strength.
Target cut suggests reduced upside expectations.
Twist could see slight buying interest.
Analyst target cut suggests reduced upside for the stock.
Analyst target cut suggests weaker outlook.
AlphAI scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Green Paula (SVP of Human Resources) sold 20,429 shares of Twist Bioscience Corp (TWST) on 2026-11-12.
Barclays maintained Twist Bioscience's Overweight rating but lowered its price target to $130 from $215, a 39.5% decrease. The new target implies a 16.5% upside from the Nov 13 close of $111.60. Recent analyst price targets for Twist range from $135 to $175.
ARK Invest added $16.2M to NVIDIA (NVDA) and $16M to CoreWeave (CRWV), while reducing positions in Tempus AI (TEM) and Palantir (PLTR) by $12.8M and $11.8M, respectively. Other buys included ACHR, TWST, PRME, and SOFI. Sells included AMZN, TER, SNPS, AVGO, XYZ, and BYDDY.
TD Cowen kept Twist Bioscience's rating at Buy but reduced its price target to $137 from $190, a 27.9% cut. This implies a 19.9% upside from the Nov 12 close of $114.22, according to the firm.
Canaccord Genuity kept its Buy rating on Twist Bioscience but reduced its price target to $150 from $205, a 26.8% cut. This implies a 31.3% upside from the Nov 12 close of $114.22.
Baird retained its Outperform rating for Twist Bioscience but reduced its price target from $187 to $135, a 27.8% decrease. This implies an 18.2% upside from the Nov 12 close of $114.22, according to the firm.
ARK Investment Management, led by Cathie Wood, disclosed $75.53M in stock purchases this week, including $16.16M in Nvidia (NVDA) and $16.02M in CoreWeave (CRWV). ARK also added to Archer Aviation (ACHR) and Rocket Lab (RKLB), while selling BYD (BYDDY) shares. CoreWeave reported $3.66B in revenue and a $132.5B backlog. Wood remains optimistic about AI and EV adoption.
Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.
Artisan Partners' Q3 2026 investor letter highlights Twist Bioscience (TWST) as a top performer, citing strong revenue growth and raised full-year guidance. The biotech company specializes in synthetic DNA products, with shares up 310% over the past year despite a recent pullback. Artisan notes AI-driven demand and management's EBITDA breakeven target as key growth drivers.
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 — — Record revenue of $126.6 million in 4QFY26 ; Increase of approximately